Borgeson Blake 4

What Happened

• Blake Borgeson, a director of Recursion Pharmaceuticals (RXRX), sold 30,000 shares on June 2, 2026. The shares were disposed at $3.68 per share, for a total value of $110,400. This was a sale (not a purchase), which is often routine insider liquidity rather than a direct signal of company prospects.

Key Details

• Transaction date and price: 2026-06-02 at $3.68 per share
• Shares sold / value: 30,000 shares for $110,400
• Transaction type: Sale (reported as “S” — open-market or private sale)
• Footnote: Transaction executed pursuant to a Rule 10b5-1 trading plan adopted Aug 31, 2025
• Shares owned after transaction: Not specified in the provided filing excerpt
• Filing timeliness: Report filed 2026-06-04; no late filing indicated

Context

• A 10b5-1 trading plan allows insiders to sell shares on a preset schedule, which can make such sales routine and not necessarily reflective of the insider’s current view of the company. Sales are generally less informative than purchases for gauging insider sentiment.